Back to top
more

Avid Bioservices (CDMO)

(Delayed Data from NSDQ)

$6.83 USD

6.83
1,441,949

+0.15 (2.25%)

Updated Apr 24, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value D Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CDMO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Avid Bioservices, Inc falls in the month of April.

All items in Millions except Per Share data.

4/30/2023 4/30/2022 4/30/2021 4/30/2020 4/30/2019
Assets          
Cash & Equivalents 39 126 170 36 32
Receivables 18 21 19 9 7
Notes Receivable 0 0 0 0 0
Inventories 44 26 12 11 7
Other Current Assets 12 7 7 4 5
Total Current Assets 112 180 208 60 51
Net Property & Equipment 177 93 37 27 26
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 114 115 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 5 5 2 1 1
Total Assets 451 430 266 108 78
Liabilities & Shareholders Equity 4/30/2023 4/30/2022 4/30/2021 4/30/2020 4/30/2019
Notes Payable 0 0 0 4 0
Accounts Payable 25 10 9 6 4
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 9 8 9 3 4
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 39 55 52 30 15
Total Current Liabilities 74 76 71 44 23
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 0 2
Convertible Debt 141 140 97 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 2 2 0 0 0
Other Non-Current Liabilities 0 0 0 0 0
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 262 255 188 66 25
Shareholders Equity 4/30/2023 4/30/2022 4/30/2021 4/30/2020 4/30/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 620 606 638 613 614
Retained Earnings -431 -431 -560 -571 -561
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 189 175 78 42 53
Total Liabilities & Shareholder's Equity 451 430 266 108 78
Total Common Equity 189 175 78 42 53
Shares Outstanding 62.50 61.70 60.80 56.40 56.00
Book Value Per Share 3.03 2.83 1.28 0.74 0.95

Fiscal Year End for Avid Bioservices, Inc falls in the month of April.

All items in Millions except Per Share data.

1/31/2024 10/31/2023 7/31/2023 4/30/2023 1/31/2023
Assets          
Cash & Equivalents -99,999 31 25 39 60
Receivables NA 13 16 18 15
Notes Receivable NA 0 0 0 0
Inventories NA 39 41 44 45
Other Current Assets NA 21 16 12 13
Total Current Assets NA 104 98 112 132
Net Property & Equipment NA 187 182 177 164
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 117 114 114 115
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 5 5 5 5
Total Assets NA 455 442 451 450
Liabilities & Shareholders Equity 1/31/2024 10/31/2023 7/31/2023 4/30/2023 1/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 23 23 25 36
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 4 5 9 8
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 49 35 39 40
Total Current Liabilities NA 77 64 74 87
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 141 141 141 140
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 8 1 2 2
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 271 252 262 265
Shareholders Equity 1/31/2024 10/31/2023 7/31/2023 4/30/2023 1/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 0 0 0 0
Capital Surplus NA 626 623 620 616
Retained Earnings NA -442 -433 -431 -431
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 184 191 189 185
Total Liabilities & Shareholder's Equity NA 455 442 451 450
Total Common Equity 0 184 191 189 185
Shares Outstanding 63.20 63.20 63.10 62.50 62.30
Book Value Per Share 0.00 2.91 3.02 3.03 2.98